[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pancreas-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pancreas-disease":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,46,70,93,120,155,178,200,228,251],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":4},"100648018","development-and-prospective-validation-of-an-ai-based-diagnostic-model-for-hepato-pancreato-biliary-diseases-100648018",false,"NCT07716670","Development and Prospective Validation of an AI-Based Diagnostic Model for Hepato-Pancreato-Biliary Diseases","Inclusion Criteria:\n\n* Age and Gender: Patients aged 18 to 75 years, of either sex.\n* Clinical Diagnosis Requirements: Suspected or confirmed hepatobiliary or pancreatic diseases (e.g., liver cancer, pancreatic cancer, cholangiocarcinoma, cirrhosis) based on preliminary clinical evaluation.\n* Ability to provide a complete medical history and symptoms for AI system interaction.\n* Cognitive and Physical Capacity:\n* Sufficient cognitive function to complete interactions with the AI multi-agent system independently (verified by Mini-Mental State Examination \\[MMSE\\] score ≥24).\n* Proficiency in Mandarin or English to ensure accurate communication with the system.\n* Consent and Compliance: Willingness to participate and provide written informed consent.\n* Ability to complete all study procedures, including physician consultations and follow-up assessments.\n* Clinical Workflow Compatibility: Scheduled for outpatient consultation at participating healthcare facilities.\n\nExclusion Criteria:\n\n* Patients with life-threatening conditions requiring immediate intervention (e.g., acute hepatic failure, severe hemorrhage).\n* Presence of severe cardiovascular or cerebrovascular diseases that may interfere with study participation.\n* Cognitive or Communication Barriers:\n* Cognitive impairment (MMSE score \\\u003C24) or language barriers preventing effective interaction with the AI system.\n* Psychiatric disorders or altered mental status affecting decision-making capacity.\n* Prior or Concurrent Participation:\n* Enrollment in other interventional clinical trials that may confound the study outcomes.\n* Current use of experimental diagnostic tools or AI systems outside the study protocol.\n* Technical or Logistical Constraints:\n* Inability to access or operate electronic devices required for AI system interaction (e.g., touchscreen terminals, mobile apps).\n* Lack of stable internet connectivity for system access.\n* Ethical or Legal Restrictions: Pregnancy or lactation (to avoid potential risks not directly related to the study).",true,"ALL","18 Years",{"count":19,"type":20},400,"ESTIMATED","4 Weeks","OBSERVATIONAL","The rapid advancement of artificial intelligence (AI) has expanded its applications in healthcare, particularly in diagnostic assistance, intelligent triage, and patient interaction. Hepatobiliary and pancreatic diseases (such as liver cancer, pancreatic cancer, cirrhosis) are characterized by insidious onset, rapid progression, low early-diagnosis rates, and poor prognosis. However, grassroots medical institutions in China face challenges including physician shortages, variable patient health literacy, and incomplete initial information collection, leading to high misdiagnosis\u002Fmissed diagnosis risks.\n\nRecent breakthroughs in large language models (LLMs) and multi-agent systems (MAS) offer new solutions. LLMs enable advanced natural language processing, while MAS coordinates specialized agents for complex decision-making. Integrating MAS with medical LLMs could create intelligent pre-consultation systems that systematically collect patient symptoms, risk factors, family history, and lifestyle data to enhance diagnostic efficiency.\n\nThis study aims to develop a MAS-based pre-consultation system for hepatobiliary-pancreatic diseases featuring four specialized agents (\"guidance agent,\" \"medical history agent,\" \"risk assessment agent,\" and \"summary generation agent\"). The system will simulate clinical reasoning to generate structured diagnostic reports for physicians.\n\nResearch Objectives:\n\nDevelop a specialized multi-agent framework combining LLMs to simulate clinical diagnostic logic and standardize symptom collection Enhance pre-consultation data integrity through intelligent dialogue focusing on key disease indicators Generate structured diagnostic summaries highlighting critical symptoms and risk factors Establish foundation for clinical validation and application through expert evaluation and user feedback This pre-diagnostic tool will assist physicians rather than replace clinical judgment, promoting safe, effective AI applications in early disease screening and tiered healthcare systems.",[25,26,27,28],"Hepatic Disease","Biliary Disease","Pancreas Disease","Artificial Intelligence (AI) in Diagnosis",[30,31,32,33],"hepatic disease","biliary disease","pancreas disease","artificial intelligence in diagnosis","NOT_YET_RECRUITING","2026-07-15",{"date":37,"type":38},"2026-07-21","ACTUAL",{"date":40,"type":20},"2026-08-15",{"date":42,"type":20},"2026-11-30",{"name":44,"class":45},"Second Affiliated Hospital, School of Medicine, Zhejiang University","OTHER",{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":69},"100642104","a-combination-of-rectal-indomethacin-and-cold-water-exposure-of-the-ampulla-after-ercp-is-superior-to-rectal-indomethacin-alone-in-reducing-the-incidence-of-post-ercp-pancreatitis--rct-100642104","NCT07574970","A COMBINATION OF RECTAL INDOMETHACIN AND COLD WATER EXPOSURE OF THE AMPULLA AFTER ERCP IS SUPERIOR TO RECTAL INDOMETHACIN ALONE IN REDUCING THE INCIDENCE OF POST-ERCP PANCREATITIS -RCT","A COMBINATION OF RECTAL INDOMETHACIN AND COLD WATER EXPOSURE OF THE AMPULLA AFTER ERCP IS SUPERIOR TO RECTAL INDOMETHACIN ALONE IN REDUCING THE INCIDENCE OF PEP","ERCP","Inclusion Criteria:\n\n1. Standard ERCP indication\n2. Consent given\n\nExclusion Criteria:\n\n1. Pregnancy and lactation\n2. Chronic calcific pancreatitis \u002F pancreatic divisum \u002F pancreatic head\n3. malignancy \u002F acute pancreatitis within 14 days of ERCP\n4. ERCP for biliary\u002Fpancreatic stent exchange or removal or prior biliary sphincterotomy\n5. Chronic kidney disease with GFR \\\u003C30 or acute kidney injury.\n6. Presence of rectal anomaly\n7. Active GI bleeding or high bleeding risk precluding NSAIDs;platelet \\\u003C50000\u002FL;INR \\>1.5 not correctable\n8. NSAID allergy\n9. Cirrhosis Child-Pugh C\n10. Temp instability or severe cardiopulmonary disease precluding cooling\u002Fshock risk.\n11. Sphincter of Oddi dysfunction (Type 3)","60 Years",{"count":56,"type":20},150,"Endoscopic retrograde cholangiopancreatography (ERCP) has emerged as the primary modality in the management of biliary and pancreatic disease. The complications occurring from ERCP can range from mild to fatal. Procedure related complications are Pancreatitis , Bleeding , Infections- Cholangitis, Cholecystitis , Perforations of which Post-ERCP pancreatitis (PEP) is the most common serious adverse event. Reported incidence of PEP is 8.6-10.7% according to studies(overall RCTs).In India it is 6.6% (2020 study). Prevention as well as early detection and management of PEP results in a satisfactory outcome. Multiple RCTs and meta-analyses show rectal indomethacin\u002Fdiclofenac significantly reduce PEP in average- and high-risk patients; now recommended by ASGE\u002FESGE for nearly all ERCPs. Other measures for prevention of PEP are prophylactic pancreatic duct stents in high-risk anatomy\u002Finstrumentation; wire-guided cannulation; minimizing PD contrast; periprocedural aggressive lactated Ringer's hydration. Cryoprevention effect was shown to reduce postprocedure papillary edema and thus lower the risk of PEP\n\n1. Rectal NSAIDs reduce but do not eliminate PEP.\n2. Cold-water ampullary cooling is biologically plausible but under-studied.\n3. First study to demonstrate if combination of rectal indomethacin and cold-water irrigation may have a synergistic effect.\n4. First study in Indian population.",[27],"RECRUITING","2026-06-10",{"date":62,"type":38},"2026-06-12",{"date":64,"type":38},"2025-12-01",{"date":66,"type":20},"2026-12-30",{"name":68,"class":45},"Asian Institute of Gastroenterology, India",1,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":16,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":80,"conditions":81,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":69},"100613167","time-to-post-operative-recovery-of-serum-albumin-as-a-predictor-of-outcome-in-major-hepato-pancreato-biliary-surgeries-100613167","NCT07263061","Time to Post-operative Recovery of Serum Albumin as a Predictor of Outcome in Major Hepato Pancreato Biliary Surgeries","Inclusion Criteria:\n\n1. All patients undergoing major Hepato pancreatico Biliary surgeries.\n2. Patients who are more than 12 years of age\n3. Retrospective arm - Data from 2010\n\nExclusion Criteria:\n\n1. Patients who refuse or are unable to give consent.\n2. Patients with Nephrotic syndrome, Protein losing enteropathies, Inflammatory bowel\n3. Disease, Chronic Liver Disease.\n4. Emergency Surgeries","13 Years","80 Years",{"count":79,"type":20},1000,"Hepatobiliary and Pancreatic surgery is associated with substantial risk of postoperative complications. Albumin is a negative acute phase protein. Its rapid decline may be due to degree of inflammation due to surgical procedures. The decline may due to multifactorial causes. Currently, contemporary data regarding the time to recovery of albumin, as a marker for early recovery of patient from surgical stress is sparse. Delta albumin is influenced by perioperative fluid administration and albumin supplementation. Delta albumin may not reflect the true surgical stress. Early post op albumin is a reflection of intraoperative events and not postoperative recovery or events and is unpredictable. Shorter recovery time of albumin is associated with less post op complications and hospital stay. Earlier recovery of albumin predicts lower morbidity and shorter hospital stay.",[82,27,83],"Hepatobiliary Disease","Bile Duct Diseases","2025-12-24",{"date":86,"type":38},"2025-12-31",{"date":88,"type":38},"2025-12-07",{"date":90,"type":20},"2026-10-23",{"name":92,"class":45},"Institute of Liver and Biliary Sciences, India",{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":97,"acronym":4,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":99,"enrollmentInfo":100,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":102,"conditions":103,"keywords":106,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":69},"100559472","artificial-intelligence-in-endoscopic-ultrasound-100559472","NCT06564571","Artificial Intelligence in Endoscopic Ultrasound","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Any patient undergoing endoscopic ultrasound examination\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years","100 Years",{"count":101,"type":20},310,"The objective of the study is to determine if this artificial intelligence system is capable of detecting abnormalities in the pancreas that are identified by an endoscopist at endoscopic ultrasound procedures.",[104,27,105],"Pancreatic Cancer","Pancreatic Cyst",[107,108,109,110],"pancreatic disease","pancreatic cancer","pancreatic cyst","artificial intelligence","2025-05-27",{"date":113,"type":38},"2025-05-31",{"date":115,"type":38},"2024-01-19",{"date":117,"type":20},"2027-12",{"name":119,"class":45},"Orlando Health, Inc.",{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":126,"eligibilityCriteria":127,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":77,"enrollmentInfo":128,"targetDuration":4,"studyType":130,"phases":131,"briefSummary":133,"conditions":134,"keywords":139,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":69},"100420906","intermittent-fasting-for-pancreatitis-100420906","NCT04760847","Intermittent Fasting for Pancreatitis","Intermittent Fasting as a Primary Means for Improving Quality of Life for Acute and Chronic Pancreatitis","IFPanc","Inclusion Criteria:\n\n* Age ≥ 18 year\n* Recurrent acute pancreatitis defined by greater than 2 episodes of pancreatitis, defined by:\n\nabdominal pain and either amylase or lipase \\> 3 x the upper limit of normal, imaging suggestive of, separated by time\n\n* Anatomy of chronic pancreatitis defined by Rosemont criterion9 or on imaging (CT, MRI)\n* Pancreatic exocrine insufficiency defined by a pancreatic elastase \\\u003C 200 ug\u002Fg stool10\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Pregnant Patients\n* Age \\> 80 years\n* Patients who cannot consent for themselves\n* Glycogen storage disease\n* Insulinoma or hypoglycemic state\n* Active alcohol abuse\n* Alcohol induced acute pancreatitis\n* Gallstone induced acute pancreatitis\n* Pancreatic solid neoplasm\n* Patients with diabetes\n* Patients on beta blockers",{"count":129,"type":20},64,"INTERVENTIONAL",[132],"NA","The purpose of this research is to compare intermittent fasting with a standard diet approach for improving the quality of life related to your pancreas disease. Our hope is to improve your symptoms and prevent you from needing to go into the hospital for pancreas-related issues.",[135,136,137,27,138],"Pancreatitis","Pancreatitis, Acute","Pancreatitis, Chronic","Acute Recurrent Pancreatitis",[140,141,142,143,144,145],"pancreatitis","acute pancreatitis","acute recurrent pancreatitis","chronic pancreatitis","fasting","intermittent fasting","2025-04-21",{"date":148,"type":38},"2025-04-22",{"date":150,"type":20},"2026-03",{"date":152,"type":20},"2026-04-01",{"name":154,"class":45},"H. Lee Moffitt Cancer Center and Research Institute",{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":159,"acronym":4,"eligibilityCriteria":160,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":161,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":163,"conditions":164,"keywords":165,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":69},"100305793","bio-repository-of-high-risk-cohorts-for-the-early-detection-of-pancreas-cancer-100305793","NCT03260842","Bio-Repository of High Risk Cohorts for the Early Detection of Pancreas Cancer","Inclusion Criteria:\n\n* Older than 18 with pancreas cyst\n* Older than 18 at high risk for Pancreas cancer\n\nExclusion Criteria:\n\n* Unable to provide consent\n* Not willing to provide bio-specimens",{"count":162,"type":20},500,"Bio-repository to collect bio-specimens from patients with 1) pancreatic cysts and 2) patients at high risk, defined by family history and\u002For genetic mutations, for pancreatic cancer.",[105,27],[166,167,168],"early detection","biomarkers","pancreas cancer","2025-03-26",{"date":171,"type":38},"2025-04-01",{"date":173,"type":38},"2017-09-01",{"date":175,"type":20},"2030-04-30",{"name":177,"class":45},"Stanford University",{"id":179,"slug":180,"hasResults":11,"nctId":181,"briefTitle":182,"officialTitle":182,"acronym":183,"eligibilityCriteria":184,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":185,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":187,"conditions":188,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":69},"100494125","radiology-registry-on-pancreatic-malignancies-100494125","NCT05714111","Radiology Registry on Pancreatic Malignancies","RadonPams","Inclusion Criteria:\n\n* ≥18 years of age\n* Patients with suspect (planned for investigation) or diagnosed pancreatic cancer at any stage.\n* able and willing to sign informed consent\n\nExclusion Criteria:\n\n* Patients with non-primary pancreatic disease",{"count":186,"type":20},1300,"The purpose of this study is to collect all radiological data which evaluated with clinical data may help assess malignancy and prognosis of pancreatic disease.This registry aims to collect retrospective data from 2014 and prospective data until 2027 with a maximum follow-up of 3 years per patient.",[104,189,27,190],"Pancreas Neoplasm","Pancreas Cyst","2024-04-11",{"date":193,"type":38},"2024-04-12",{"date":195,"type":38},"2022-03-04",{"date":197,"type":20},"2030-03-30",{"name":199,"class":45},"IRCCS San Raffaele",{"id":201,"slug":202,"hasResults":11,"nctId":203,"briefTitle":204,"officialTitle":205,"acronym":206,"eligibilityCriteria":207,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":208,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":210,"conditions":211,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":220,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":69},"100466615","survival-quality-of-life-and-resectability-in-locally-advanced-pancreatic-cancer-100466615","NCT05356039","Survival, Quality of Life and Resectability in Locally Advanced Pancreatic Cancer","Survival, Quality of Life and Resectability in Locally Advanced Pancreatic Cancer - a Multicenter Prospective Observational Study","SQUARE","Inclusion Criteria:\n\n* Confirmed or suspected invasive pancreatic primary tumor\n* Tumor classified as borderline resectable or locally advanced disease according to NCCN guidelines\n\nExclusion Criteria:\n\n* Suspected endocrine tumor\n* Suspected non-pancreatic periampullary tumor\n* Distant metastasis\n* Age \\\u003C 18 years\n* Patient unable to understand verbal or written information interfering with informed consent or treatment\n* Mental or organic disorder interfering with informed consent or treatments",{"count":209,"type":20},300,"This study aims to assess overall survival, quality of life and resection rates in locally advanced pancreatic cancer",[212,189,27,213,214,215,216,217,218],"Pancreas Cancer","Pancreas Adenocarcinoma","Surgery","Chemotherapy Effect","Quality of Life","Locally Advanced Pancreatic Adenocarcinoma","Borderline Resectable Pancreatic Adenocarcinoma","2022-11-23",{"date":221,"type":38},"2022-11-30",{"date":223,"type":38},"2022-04-19",{"date":225,"type":20},"2028-05",{"name":227,"class":45},"Umeå University",{"id":229,"slug":230,"hasResults":11,"nctId":231,"briefTitle":232,"officialTitle":233,"acronym":4,"eligibilityCriteria":234,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":235,"targetDuration":236,"studyType":22,"phases":4,"briefSummary":237,"conditions":238,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":243,"lastUpdatePostDateStruct":244,"startDateStruct":246,"completionDateStruct":248,"leadSponsor":250,"locationsCount":69},"100451236","prognostic-factors-in-periampullary-tumors-and-cysts-100451236","NCT05155878","Prognostic Factors in Periampullary Tumors and Cysts","Prognostic Factors, Operative Care and Short and Long Term Outcomes for Cysts and Tumors in Pancreas and the Periampullary Region","Inclusion Criteria:\n\n* Recommended surgery for tumor or cyst in the pancreas or periampullary region\n* Information avalible in electronic journal files\n* Informed consent (or deceased for retrospective part of the study)\n\nExclusion Criteria:\n\n* No informed consent (and still alive at study initiation)",{"count":162,"type":20},"10 Years","The project aims at analysing prognostic and predictive factors involved in diagnostics and surgical treatment of cysts and tumors in the pancreas and periampullary region using both clinical data and blood and tissue samples for biomarker development and validation.",[212,189,190,239,27,240,241,214,242],"Pancreatic Fistula","Bile Duct Cancer","Periampullary Cancer","Surgery--Complications","2021-12-13",{"date":245,"type":38},"2022-01-05",{"date":247,"type":38},"2021-09-01",{"date":249,"type":20},"2040-01-01",{"name":227,"class":45},{"id":252,"slug":253,"hasResults":11,"nctId":254,"briefTitle":255,"officialTitle":256,"acronym":257,"eligibilityCriteria":258,"healthyVolunteers":11,"sex":16,"minAge":259,"maxAge":260,"enrollmentInfo":261,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":262,"conditions":263,"keywords":266,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":268,"lastUpdatePostDateStruct":269,"startDateStruct":271,"completionDateStruct":273,"leadSponsor":275,"locationsCount":69},"100405180","results-of-surgical-treatment-of-the-hepatobiliopancreatic-surgical-unit-100405180","NCT04556019","Results of Surgical Treatment of the Hepatobiliopancreatic Surgical Unit","Results of the Surgical Treatment of Patients From Hepatobiliopancreatic Surgical Unit at the Complejo Hospitalario de Navarra","HPB","Inclusion Criteria:\n\n* All patients operated by the HPB Surgical Unit in the last 10 years (retrospective)\n* All patients being operated by the HPB Surgical Unit from January 2019 onwards who provide inform consent (prospective).\n\nExclusion Criteria:\n\n* Patients not eligible for surgery\n* Patients not interested in taking part in the study","15 Years","90 Years",{"count":79,"type":20},"The main aims of this study are:\n\n1. \\- to evaluate post-surgical morbidity and mortality outcomes, following the criteria and the definitions from Claven-Dindo and ISGPS international classifications, of the patients operated by the HPB Surgical Unit.\n2. \\- to evaluate survival and disease-free survival rates of the patients operated by the HPB Surgical Unit due to tumoral cause.",[27,264,265,83],"Liver Diseases","Surgical Procedure, Unspecified",[267],"Hepatobiliopancreatic surgery","2020-09-15",{"date":270,"type":38},"2020-09-21",{"date":272,"type":38},"2019-01-03",{"date":274,"type":20},"2029-01",{"name":276,"class":45},"Fundacion Miguel Servet"]